Abstract
ALG is mainly used for immunosuppressive treatment following organ transplants. Controlled clinical trials demonstrated the efficacy of ALG in kidney, bone marrow and skin transplantation. Pilot studies describe a therapeutic effect in human autoaggression. A possible therapeutic effect, however, depends upon the strict observation of the following criteria: adequate dosage (20 mg/kg and more); intravenous application; suppression of sensitization against xenogeneic globulin by induction of immunologic unresponsiveness before ALG-treatment (prevention of allergic complications and increase of ALG efficacy). Previously published negative results with ALG can be explained by failure to comply with the above criteria.
| Translated title of the contribution | The clinical use of antilymphocyte globulin (ALG) |
|---|---|
| Original language | German |
| Pages (from-to) | 1361-1368 |
| Number of pages | 8 |
| Journal | Munchener Medizinische Wochenschrift |
| Volume | 117 |
| Issue number | 35 |
| State | Published - 1975 |
| Externally published | Yes |